Prophylaxis in adults with haemophilia

Haemophilia

Volumn 13, Issue SUPPL. 2, 2007, Pages 10-15

  Hay, C R M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adults; Haemophilia; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; AGE DETERMINATION; ARTHROPATHY; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEMARTHROSIS; HEMOPHILIA A; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COAGULANTS; FACTOR VIII; FEMALE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 34447127750     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01500.x     Document Type: Article

References (17)

1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
2. National Hemophilia Foundation. MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). 2006; MASAC Document #170. Available at: http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/ 170.pdf. Accessed 7 February 2007.
3. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2005. Available at: http://www.wfh.org/2/docs/Publications/ Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf. Accessed 7 February 2007.
4. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
5. Blanchette P, Rivard G, Israels S et al. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia 2004; 10: 679-83.
6. Plug I, van der Bom JG, Peters M et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
7. Fischer K, van der Bom JG, Molho P et al. Prophylactic vs. on-demand treatment strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
8. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
9. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
10. Carlsson KS, Hojgard S, Lindgren A et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26.
11. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
12. Carlsson KS, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: Differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
13. Berntorp E. Prophylactic therapy for haemophilia: Early experience. Haemophilia 2003; 9: 5-9.
14. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
15. Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: Incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
16. Fischer K, van Dijk K, van den Berg M. Results of prophylaxis started in adulthood. Haemophilia 2006; 10: 113-16 [abstract 22 OC 06].
17. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-40.